Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03030612
Recruitment Status : Active, not recruiting
First Posted : January 25, 2017
Last Update Posted : July 17, 2020
Sponsor:
Collaborator:
argenx
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Brief Summary:
The purpose of this study is to determine the maximum tolerated dose (MTD) of ARGX-110 and/or the recommended Phase II dose (RP2D) in combination with a standard dose of azacytidine (AZA) in Phase 1; and to evaluate efficacy of ARGX-110 when administered at a RP2D level established in Phase I in combination with a standard dose of AZA (proof-of concept) by evaluating overall response rate (ORR) in Phase 2.

Condition or disease Intervention/treatment Phase
Leukemia, Myeloid, Acute Myelodysplastic Syndromes Drug: ARGX-110 Drug: AZA Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II, Open-label, Dose-Escalating Study With a Proof of Concept Cohort to Evaluate the Safety, Tolerability and Efficacy of ARGX-110 in Combination With Azacytidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
Actual Study Start Date : January 2017
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020


Arm Intervention/treatment
Experimental: ARGX-110 with Azacytidine (AZA)

Phase 1: Participants will receive loading dose of ARGX-110 1 milligram per kilogram (mg/kg) body weight (cohort 1), 3 mg/kg body weight (cohort 2), 10 mg/kg body weight (cohort 3) or 20 mg/kg body weight (cohort 4) administered intravenously (IV) in combination with AZA standard dose of 75 milligram per meter square (mg/m^2) body surface area (BSA) administered subcutaneously (SC) / intravenously (IV).

Phase 2: Participants will receive loading dose of ARGX-110 IV at a recommended dose for Phase 2 (RP2D) level from phase 1 in combination with AZA standard dose of 75 mg/m^2 BSA, administered SC/IV as per local practice.

Drug: ARGX-110
ARGX-110 will be administered intravenously.
Other Names:
  • Cusatuzumab
  • JNJ-74494550

Drug: AZA
AZA will be administered subcutaneously/intravenously.




Primary Outcome Measures :
  1. Phase 1: Number of Participants with Dose Limiting Toxicity (DLT) [ Time Frame: Up to 3.6 years ]
    DLTs will be defined as any of the following drug-related events: Any grade 3 or higher drug related non-hematological toxicity or; Grade 3 or higher IRRs or; inability to administer the next dose due to a drug-related adverse event or a delay of the administration of the next dose due to toxicities for more than 14 days despite adequate medication or; drug-related grade 4 febrile neutropenia or; drug-related grade 4 anemia which cannot be adequately treated.

  2. Phase 2: Overall Response Rate (ORR) [ Time Frame: Up to 3.6 years ]
    ORR is defined as the sum of Complete remission (CR), CR with incomplete recovery (CRi), morphologic leukemia-free state (MLFS), partial remission (PR) at the ARGX-110 RP2D level that was established in Phase 1 according to established response criteria for Acute myeloid leukemia (AML).


Secondary Outcome Measures :
  1. Phase 1 and Phase 2: Number of Participants with Adverse Events [ Time Frame: Up to 3.6 years ]
    An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

  2. Phase 1 and Phase 2: Maximum Observed Concentration (Cmax) of ARGX-110 [ Time Frame: Up to 3.6 years ]
    Cmax is the maximum observed concentration.

  3. Phase 1 and Phase 2: Trough Concentration (Ctrough) of ARGX-110 [ Time Frame: Up to 3.6 years ]
    Ctrough is defined as the observed serum concentration before dosing or at the end of the dosing interval.

  4. Phase 1 and Phase 2: Area Under the Serum Concentration-Time Curve from Time Zero to Infinite (AUC[0-infinity]) of ARGX-110 [ Time Frame: Up to 3.6 years ]
    AUC(0-infinity) is defined as area under the serum analyte concentration-time curve from time 0 to infinite time of ARGX-110.

  5. Phase 1 and Phase 2: Area Under the Serum Concentration-Time Curve During the Dosing Interval (AUCtau) [ Time Frame: Up to 3.6 years ]
    AUCtau is the area under the serum concentration-time curve during the dosing interval.

  6. Phase 1 and Phase 2: Apparent Volume of Distribution (Vd/F) of ARGX-110 [ Time Frame: Up to 3.6 years ]
    Vd/F is defined as Dose/[Lambda (z)*AUC (0-infinity)].

  7. Phase 1 and Phase 2: Total Systemic Clearance (CL) of ARGX-110 [ Time Frame: Up to 3.6 years ]
    CL is the total systemic clearance of drug after intravenous (IV) administration.

  8. Phase 1 and Phase 2: Elimination Half-Life (t1/2) of ARGX-110 [ Time Frame: Up to 3.6 years ]
    t1/2 is defined as the time measured for the serum concentration to decrease by 1 half of its original concentration.

  9. Phase 1 and Phase 2: Number of Participants with Minimal Residual Disease (MRD) to ARGX-110 [ Time Frame: Up to 3.6 years ]
    Minimal residual disease assessments will be performed on bone marrow aspirates and/or whole blood by flow cytometry.

  10. Phase 1 and Phase 2: Number of Participants with Anti-drug Antibodies (ADA) to ARGX-110 [ Time Frame: Up to 3.6 years ]
    Venous blood samples and bone marrow aspirate will be used to evaluate presence of anti-drug antibodies to ARGX-110. Participants with titer of confirmed positive samples for ARGX-110 antibodies will be reported.

  11. Phase 1 and Phase 2: Number of Participants with Complete Remission (CR) [ Time Frame: Up to 3.6 years ]
    Complete remission is defined as number of participants who have bone marrow blasts less than (<) 5 percent (%); absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count greater than (>) 1.0 * 10^9 per liter (L) (1000 per microliter [µL]); platelet count > 100 * 10^9/L (100.000/mc); independence of red cell transfusions.

  12. Phase 1 and Phase 2: Number of Participants with CR with Incomplete Recovery (CRi) [ Time Frame: Up to 3.6 years ]
    CRi is defined as number of participants who have all CR criteria except for residual neutropenia (< 1.0 * 10^9/L [1000/mc]) or thrombocytopenia (< 100 * 10^9/L [100.000/mc]).

  13. Phase 1 and Phase 2: Number of Participants with Morphologic Leukemia-free State (MLFS) [ Time Frame: Up to 3.6 years ]
    MLFS is defined as number of participants who have bone marrow blasts < 5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required.

  14. Phase 1 and Phase 2: Number of Participants with Partial remission (PR) [ Time Frame: Up to 3.6 years ]
    PR is defined as number of participants who have all hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%.

  15. Phase 1 and Phase 2: Time to Response [ Time Frame: Up to 3.6 years ]
    Time to response is defined as response measured from the time from first dose of study drug to date of response (CR, CRi, MLFS, PR).

  16. Phase 1 and Phase 2: Duration of Response [ Time Frame: Up to 3.6 years ]
    Duration of response is defined as the date of achievement of a response (CR, CRi, MLFS, PR) until the date of relapse.

  17. Phase 1 and Phase 2: Relapse-Free Survival (RFS) [ Time Frame: Up to 3.6 years ]
    RFS is defined as disease relapse or participant death from any cause; measured from the date of achievement of a remission (CR, CRi) until the date of relapse or death from any cause.

  18. Phase 1 and Phase 2: Overall Survival (OS) [ Time Frame: Up to 3.6 years ]
    OS is defined as death from any cause; measured from the date of first dose to the date of death from any cause.

  19. Phase 1 and Phase 2: Number of Participants with 30 Day and 60 Day Mortality [ Time Frame: 30 and/or 60 days after the first administration ]
    Number of participants with 30 Day and 60 Day Mortality will be reported.

  20. Phase 1 and Phase 2: Number of Participants Achieving Transfusion Independence (TI) [ Time Frame: Up to 3.6 years ]
    Number of participants reaching greater than or equal to (>=) 8 consecutive weeks without red blood cell (RBC-TI) and/or platelet (PLT-TI) transfusion. The first day of the >=8-week period with no transfusions is noted as the time at which participants first achieved TI.

  21. Phase 1 and Phase 2: Time to Transfusion Independence [ Time Frame: Up to 3.6 years ]
    Time until TI for RBC and/or PLT will be measured from the date of entry into a study to the first day of the 8-weeks period with no transfusions.

  22. Phase 1 and Phase 2: Duration of Transfusion Independence [ Time Frame: Up to 3.6 years ]
    Time between the last transfusion before the start of the TI period and the first transfusion after the start of the TI period, which occurred >=8 weeks later.

  23. Phase 1 and Phase 2: Time to Neutrophil Recovery [ Time Frame: Up to 3.6 years ]
    Time to neutrophil recovery will be calculated from number of days from Day 1 of commencing study treatment to first day neutrophils 0.5 * 10^9 per liter or 1.0 * 10^9 per liter.

  24. Phase 1 and Phase 2: Time to Platelet Recovery [ Time Frame: Up to 3.6 years ]
    Time to platelet recovery will be calculated from number of days from day 1 of commencing study treatment to first day neutrophils 50 * 10^9 per liter or 100 * 10^9 per liter.

  25. Biomarker Assessment of ARGX-110 [ Time Frame: Up to 3.6 years ]
    Biomarkers including CD70 and CD27 assessment will be performed on bone marrow aspirates and/or whole blood.

  26. Phase 1: Levels of T, B and NK Cells [ Time Frame: Up to 3.6 years ]
    Levels of T, B and NK cells will be reported by immunophenotyping (performed by flow cytometry or mass cytometry). .

  27. Phase 1: Levels of B Cells [ Time Frame: Up to 3.6 years ]
    Levels of B cells will be reported.

  28. Phase 1: Levels of NK Cells [ Time Frame: Up to 3.6 years ]
    Levels of NK cells will be reported.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent form (ICF) indicating an understanding of the purposes, risks, and procedures required for the study and willingness and ability to participate in the study
  • Acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS) (according to 2016 World Health Organization [WHO] classification definition of greater than or equal to [>=] 20 percent [%] blasts) (bone marrow) unsuitable for intensive treatment (including stem cell transplantation) with a curative intent, but eligible to receive azacytidine (AZA) treatment
  • Expected life expectancy >= 3 months, at the discretion of the investigator
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  • Women of childbearing potential having a negative serum pregnancy test at screening and within 48 hours before infusion of ARGX-110 on Day -14, and willing to use an effective contraceptive method (intrauterine devices, hormonal contraceptives, contraceptive pill, implants, transdermal patches, hormonal vaginal devices, infusions with prolonged release) during the study and for at least 3 months after the last study drug administration

Exclusion Criteria:

  • Prior or concurrent malignancy, except for the following: (1) adequately treated basal cell or squamous cell skin cancer; (2) carcinoma in situ of the cervix; (3) carcinoma in situ of the breast; (4) incidental histological finding of Prostate cancer (Tumour, Node, Metastasis [TNM] stage T1a or T1b), or; (5) Any other cancer from which the subject has been disease-free for more than 2 years
  • Any previous AML or MDS chemo- or radiotherapy (with the exception of hydroxyurea/Litalir for leukocyte control which should be discontinued by the first day of AZA, local radiation therapy, therapy for basal or squamous cell carcinoma of the skin)
  • Treatment with any investigational product within 4 weeks before the first administration of ARGX-110
  • Any known active or chronic infection, including human immunodeficiency virus (HIV) and hepatitis B or C virus infection
  • Any other concurrent disease or medical condition that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03030612


Locations
Layout table for location information
France
Marseille Cedex 9, France
Paris Cedex 10, France
Pierre - Bénite cedex, France
Toulouse Cedex 9, France
Switzerland
Aarau, Switzerland
Bern, Switzerland
Zürich, Switzerland
Sponsors and Collaborators
Janssen Research & Development, LLC
argenx
Investigators
Layout table for investigator information
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT03030612    
Other Study ID Numbers: CR108756
2016-002151-17 ( EudraCT Number )
ARGX-110-1601 ( Other Identifier: Janssen Research & Development, LLC )
First Posted: January 25, 2017    Key Record Dates
Last Update Posted: July 17, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.

As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

URL: https://www.janssen.com/clinical-trials/transparency

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Syndrome
Disease
Pathologic Processes
Neoplasms by Histologic Type
Neoplasms
Bone Marrow Diseases
Hematologic Diseases